BC Cancer Protocol Summary for Suppressive Therapy for Pituitary Adenomas using Cabergoline

Protocol Code	*CNCAB*
Tumour Group	*Neuro-Oncology*
Contact Physician	*Dr. Rebecca Harrison*

ELIGIBILITY:

Patients must have:

- Pituitary adenomas producing prolactin (prolactinoma) or growth hormone

EXCLUSIONS:

- Pregnant or breast feeding women

CAUTION:

- Uncontrolled hypertension

TESTS:

- Baseline: Prolactin level, CT or MRI pituitary, pregnancy test if applicable, visual field and vision assessment if macroadenoma.
- At 4 weeks, repeat prolactin level, then repeated as clinically indicated
- At 6 months, prolactin level and CT pituitary; thereafter, prolactin level annually
- If clinically indicated: CT pituitary
- For macroadenoma, confirm improvement in any visual field and vision abnormalities before continuing cabergoline on a long term basis

PREMEDICATIONS:

- None

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
cabergoline	0.5 mg twice a week	PO with food

Activated: 1 Jul 2001 Revised: 1 Feb 2022 (institution name updated, eligibility and exclusions clarified, contact revised)
Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use.

DOSE MODIFICATIONS:

1. **Dose Titration:**
- Titrate dose upward according to prolactin level
- If prolactin normalises, reduce to the lowest dose that maintains it in normal range

2. **Visual Field Abnormalities:**
- if present at baseline, start cabergoline at 1mg twice a week
- reduce dose only after visual field abnormalities have normalised and tumour shrinkage confirmed with imaging

PRECAUTIONS

1. **Hypotension**: may occur during the first few days of treatment
2. **Pregnancy**: seek medical advice if pregnancy occurs during treatment.

Call Dr. Rebecca Harrison or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use.